Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2021 FY- Text added to 2022 FY
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
ADC, antibody, antigen, Asa, attached, Australian, Benjamin, biggest, Biopharma, Cao, car, Compugen, consecutive, consummation, covalently, CSC, cutting, Dean, default, Dekel, edge, effectuated, eighty, Eli, enriched, era, extracellular, fifteen, firstly, forbear, forbearance, Fu, gemtuzumab, GI, Goldberg, greatly, Han, Horovitz, hundred, IARC, ideally, Importantly, incidence, inoculated, insolvency, lender, Li, linker, lowest, MC, monoclonal, Mylotarg, navigation, Nephrology, ozogamicin, partnership, polymer, Polypoid, predominantly, projected, ranking, Regenerative, reserved, restated, Rotterdam, Sanja, Sig, SPA, Sun, synergism, tageza, Ther, thereunder, TIC, tranche, Transduct, tumour, twenty, unpaid, unresponsive
Valuein 2021 FY filing- Value in 2022 FY filing
Original filings
Filing view